FREE Account Opening + No Clearing Fees
Loading...

Cell Point NSE SME IPO review (Avoid)

Review By Dilip Davda on June 11, 2023

•    CPIL is engaged in multi-brand retail selling of smartphones, and electronic items.
•    It is a south-centric retailer with operations in Andhra Pradesh only.
•    After average financial performance till FY22, it posted super margins for 9M-FY23.
•    Based on FY23 annualized working, the issue appears greedily priced. 
•    There is no harm in skipping this pricey bet.

ABOUT COMPANY:
Cell Point (India) Ltd. (CPIL) is engaged in multi-brand retail selling of Smart Phones, tablets, mobile accessories and mobile-related products and allied accessories of various brands such as Apple, Samsung, Oppo, Realme, Nokia, Vivo, Xiaomi, Redmi, Techno, One Plus, GIONEE, VIVO etc. It is also engaged in retail selling of some of the consumer durable electronics goods, specifically, smart televisions of various brands such as Xiaomi, Realme and One Plus. 

All products are sold under one roof through its 75 retail store chain located all over Andhra Pradesh. The company also provides payment options such as credit/EMI facilities including UPI, vouchers, & pay on-delivery to its customers for buying products for which the company has tied up with major leading credit houses like Bajaj Finserv, Capital First, TVS Credit Finance etc. The products sold by the Company enjoy limited warranty from its supplier company as back-to-back. Generally, in case of a defect, the company gets free replacement or services from the supplier Company. As of December 31, 2022, it had 298 employees on its payroll. 

ISSUE DETAILS/CAPITAL HISTORY:
The company is coming out with a maiden IPO of 5034000 equity shares of Rs. 10 each at a fixed price of Rs. 100 per share to mobilize Rs. 50.34 cr. The issue opens for subscription on June 15, 2023, and will close on June 20, 2023. The minimum application to be made is for 1000 shares and in multiples thereon, thereafter. Post allotment, shares will be listed on NSE SME Emerge. The issue constitutes 26.93% of the post-IPO paid-up capital of the company. CPIL is spending Rs. 0.80 cr. for this IPO process, and from the net proceeds, it will utilize Rs. 16.86 cr. for repayment of certain borrowings, Rs. 12.00 cr. for repairs and renovation of existing stores and setting new retail stores, Rs. 10.00 cr. for working capital and Rs. 10.68 cr. for general corporate purposes.  

First Overseas Capital Ltd. is the sole lead manager and Bigshare Services Pvt. Ltd. is the registrar of the issue. NNM Securities Pvt. Ltd. is the market maker for the company. 

Having issued entire equity shares at a par value so far, it has also issued bonus shares in the ratio of 11 for 1 in December 2022. The average cost of acquisition of shares by the promoters is Rs. 3.24, and Rs. 3.32 per share. (There is a mismatch in bonus shares issue data referred to on page no. 58 and no. 81 of the offer document). 

Post-IPO, CPIL's current paid-up equity capital of Rs. 13.65 cr. will stand enhanced to Rs. 18.69 cr. Based on the IPO pricing, the company is looking for a market cap of Rs. 186.86 cr. 

FINANCIAL PERFORMANCE:
On the financial performance front, for the last three fiscals, CPIL has posted a turnover/net profit of Rs. 278.12 cr. / Rs. 1.60 cr. (FY20), Rs. 223.56 cr. / Rs. 0.69 cr. (FY21), and Rs. 270.04 cr. / Rs. 1.65 cr. (FY22). For 9M of FY23, it earned a net profit of Rs. 5.81 cr. on a turnover of Rs. 221.68 cr. It suffered a minor setback for FY21 on account of the pandemic. Super profits for 9M-FY23 (pre-IPO year) raise eyebrows and the sustainability of such margins going forward amidst rising competition. 

The sudden jump in net margins to 2.62% for 9M-FY23 against 0.61% for FY22 raises eyebrows. Its debt as of December 31, 2022, stood at 48.80 cr. and is a major concern. 

For the last three fiscals, CPIL has reported an average EPS of Rs. 11.60 and an average RoNW of 10.55%. The issue is priced at a P/BV of 7.12 based on its NAV of Rs. 14.04 as of December 31, 2022, and at a P/BV of 2.33 based on its post-IPO NAV of Rs. 42.87 per share. 

If we annualize super FY23 earnings and attribute it to post-IPO fully diluted paid-up equity capital, then the asking price is approximately at a P/E of 24.10, and based on its FY22 earnings, the P/E stands at 113.64. Thus the issue is exorbitantly priced discounting all near-term positives. 

DIVIDEND POLICY:
The company has not declared any dividends since incorporation. It will adopt a prudent dividend policy post-listing, based on its financial performance and future prospects. 

COMPARISON WITH LISTED PEERS:
As per the offer document, the company has shown Bhatia Commu, Fone4 Commu, and Jay Jalaram as their listed peers. They are currently trading at a P/E of 23.08, 00, and 78.31 (as of June 09, 2023). However, they are not truly comparable on an apple-to-apple basis. 

MERCHANT BANKER'S TRACK RECORD:
This is the 16th mandate from First Overseas in the last four fiscals (including the ongoing one). Out of the last 10 listings, 1 opened at discount, 2 at par and the rest listed at premiums ranging from 2.50% to 43.53% on the listing date. Thus the LM has an average track record. 


Conclusion / Investment Strategy

The company operates in a highly competitive and fragmented segment with many players around. The sudden boost in its bottom line for 9M-FY23 raised eyebrows and concern over sustainability going forward. Based on such super earnings, the issue appears greedily priced, while based on its track records, it appears exorbitantly priced. There is no harm in skipping this pricey issue.

Reviewer recommends Avoid to the issue.

Review By Dilip Davda on June 11, 2023

Review Author

DISCLAIMER: No financial information whatsoever published anywhere here should be construed as an offer to buy or sell securities, or as advice to do so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions. My reviews do not cover GMP market and operators game plans. Readers must consult a qualified financial advisor before making any actual investment decisions, based the on information published here. With entry barriers, SEBI wants only well-informed investors to participate in such offers. With crazy listings in the recent past, SME IPOs drew the attention of investors across the board and lead to seer madness. However, as SME issues have entry barriers and continued low preference from the broking community, any reader taking decisions based on any information published here does so entirely at their own risk. The above information is based on information available as of date coupled with market perceptions. The Author has no plans to invest in this offer.


About Dilip Davda

Dilip Davda

Dilip Davda is veteran journalist associated with stock market since 1978. He is contributing to print and electronic media on stock markets/insurance/finance since 1985.

Dilip Davda is a leading reviewer of public issues and NCDs in the primary stock market in India. The knowledge he gained over 3 decades while working in the stock market and a strong relationship with popular lead managers makes his reviews unique. His detail fundamental and financial analysis of companies coming up with IPO helps investors in the primary stock market. Dilip Davda has a special interest in analyzing the SME companies and writing reviews about their public issues. His reviews are regularly published online and in news papers.

(Dilip Davda -SEBI registered Research Analyst-Mumbai,

Registration no. INH000003127 (Perpetual)

Email id: dilip_davda@rediffmail.com ).

Cell Point (India) IPO FAQs

  1. 1. Why Cell Point (India) IPO?

    The initial public offer (IPO) of Cell Point (India) Limited offers an early investment opportunity in Cell Point (India) Limited. A stock market investor can buy Cell Point (India) IPO shares by applying in IPO before Cell Point (India) Limited shares get listed at the stock exchanges. An investor could invest in Cell Point (India) IPO for short term listing gain or a long term.

  2. 2. How is Cell Point (India) IPO?

    Read the Cell Point (India) IPO recommendations by the leading analyst and leading stock brokers.

  3. 3. Cell Point (India) IPO what should investors do?

    Cell Point (India) IPO offers an opportunity to buy IPO shares before they get listed at the stock exchanges. Read the Cell Point (India) IPO Notes, Analysis and Recommendations by leading stock brokerage firms and experts in the above answer.

  4. 4. Is Cell Point (India) IPO good?

    Our recommendation for Cell Point (India) IPO is to avoid.

  5. 5. Is Cell Point (India) IPO worth Investing?

    As per the analysis by our lead analyst Mr. Dilip Davda, we suggest you to avoid the Cell Point (India) IPO.

  6. 6. When will Cell Point (India) IPO allotment status?

    The Cell Point (India) IPO allotment status will be available on or around June 23, 2023. The allotted shares will be credited in demat account by June 27, 2023. Visit Cell Point (India) IPO allotment status to check.

  7. 7. When will Cell Point (India) IPO list?

    The Cell Point (India) IPO will list on Wednesday, June 28, 2023, at NSE SME.